High-protein bakery items present another opportunity
On May 9, 2024, U.S
Background technique [0002] Sermaglutide is a new long-acting glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordisk, which not only has a significant hypoglycemic effect, but also has a significant weight loss effect , the drug is also the second GLP-1 hypoglycemic drug (the other is liraglutide) in Novo Nordisk's diabetes pipeline that has both hypoglycemic and weight loss effects
Clinical trials show men achieve 10-17% weight loss on semaglutide depending on dose, with efficacy and safety profiles equivalent to female populations
But the brand name, indication, device, dose strengths and price can differ depending on the company
GLP-1 agonists, through their effects on insulin secretion, glucagon suppression, and gastric emptying, are particularly effective at controlling post-meal glucose excursions